AF in Cancer Patients: A Different Need for Anticoagulation?

Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanz, Ana Pardo, Gómez, José Luis Zamorano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Pharmacotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523059/
https://www.ncbi.nlm.nih.gov/pubmed/31131040
http://dx.doi.org/10.15420/ecr.2018.32.2
_version_ 1783419245399375872
author Sanz, Ana Pardo
Gómez, José Luis Zamorano
author_facet Sanz, Ana Pardo
Gómez, José Luis Zamorano
author_sort Sanz, Ana Pardo
collection PubMed
description Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes.
format Online
Article
Text
id pubmed-6523059
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-65230592019-05-24 AF in Cancer Patients: A Different Need for Anticoagulation? Sanz, Ana Pardo Gómez, José Luis Zamorano Eur Cardiol Pharmacotherapy Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes. Radcliffe Cardiology 2019-04 /pmc/articles/PMC6523059/ /pubmed/31131040 http://dx.doi.org/10.15420/ecr.2018.32.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Pharmacotherapy
Sanz, Ana Pardo
Gómez, José Luis Zamorano
AF in Cancer Patients: A Different Need for Anticoagulation?
title AF in Cancer Patients: A Different Need for Anticoagulation?
title_full AF in Cancer Patients: A Different Need for Anticoagulation?
title_fullStr AF in Cancer Patients: A Different Need for Anticoagulation?
title_full_unstemmed AF in Cancer Patients: A Different Need for Anticoagulation?
title_short AF in Cancer Patients: A Different Need for Anticoagulation?
title_sort af in cancer patients: a different need for anticoagulation?
topic Pharmacotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523059/
https://www.ncbi.nlm.nih.gov/pubmed/31131040
http://dx.doi.org/10.15420/ecr.2018.32.2
work_keys_str_mv AT sanzanapardo afincancerpatientsadifferentneedforanticoagulation
AT gomezjoseluiszamorano afincancerpatientsadifferentneedforanticoagulation

Ejemplares similares